- Details
- Description
Packaging Size:
56T/bottle
Strength:
120mg
Composition:
Sotorasib
Treatment:
KRAS p.G12C Mutation non-small cell lung cancer (NSCLC)
Form:
Tablet
Brand:
SOTOLDX
Quantity Unit:
120mg*56T/bottle
Manufacturer:
BIGBEAR Pharma,Laos PDR
Sotorasib is in a class of medications called KRAS inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply.
Non-Small Cell Lung Cancer
Indicated for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults who have received ≥1 prior systemic therapy 960 mg PO qDay Continue until disease progression or unacceptable toxicityDosage Modifications
Dosage reduction levels for adverse reactions
- First dose reduction: 480 mg qDay
- Second dose reduction: 240 mg qDay
- Unable to tolerate 240 mg qDay: Discontinue
Related Products
